- Report
- February 2023
- 250 Pages
Global
From €3803EUR$4,000USD£3,260GBP
€4753EUR$5,000USD£4,075GBP
- Report
- December 2023
- 93 Pages
Global
From €5324EUR$5,600USD£4,564GBP
- Report
- August 2023
- 255 Pages
Global
From €7225EUR$7,600USD£6,194GBP
€9032EUR$9,500USD£7,743GBP
- Newsletter
- December 2023
Global
From €1010EUR$1,138USD£896GBP
- Report
- February 2023
- 244 Pages
Global
From €3993EUR$4,200USD£3,423GBP
- Report
- May 2023
- 51 Pages
Global
From €3327EUR$3,500USD£2,853GBP
- Report
- October 2023
- 198 Pages
Global
From €3379EUR$3,554USD£2,897GBP
€3754EUR$3,949USD£3,219GBP
- Report
- May 2023
- 250 Pages
Global
From €3803EUR$4,000USD£3,260GBP
€4753EUR$5,000USD£4,075GBP
- Report
- February 2023
- 250 Pages
Global
From €3803EUR$4,000USD£3,260GBP
€4753EUR$5,000USD£4,075GBP
- Report
- January 2023
- 125 Pages
Global
From €2367EUR$2,490USD£2,029GBP
- Report
- June 2023
- 103 Pages
Global
From €5657EUR$5,950USD£4,849GBP
- Report
- June 2023
- 144 Pages
Global
From €2138EUR$2,249USD£1,833GBP
€2376EUR$2,499USD£2,037GBP
- Report
- December 2022
- 196 Pages
Global
From €4769EUR$5,192USD£3,950GBP
- Report
- February 2023
- 178 Pages
Global
From €3838EUR$4,038USD£3,291GBP
€4516EUR$4,750USD£3,871GBP
- Report
- August 2023
- 127 Pages
Global
From €3613EUR$3,800USD£3,097GBP
€4516EUR$4,750USD£3,871GBP
- Report
- March 2023
- 164 Pages
Global
From €2377EUR$2,500USD£2,038GBP
- Report
- March 2023
- 1355 Pages
Global
From €2377EUR$2,500USD£2,038GBP
- Report
- April 2023
- 147 Pages
Global
From €5703EUR$5,999USD£4,889GBP
- Drug Pipelines
- May 2023
- 151 Pages
Global
From €10453EUR$10,995USD£8,961GBP
- Report
- February 2023
- 243 Pages
Asia Pacific
From €5276EUR$5,550USD£4,523GBP

The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone.
The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more